Quarterly report pursuant to Section 13 or 15(d)

Stock Based Compensation

v3.23.3
Stock Based Compensation
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock Based Compensation

Note 6 – Stock-Based Compensation

Equity Incentive Plans

2013 Equity Incentive Plan

Effective on June 14, 2023, the Company’s stockholders approved the amendment and restatement of the 2013 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 50,000 shares, bringing to 489,298 the total number of shares approved for issuance under that plan.

As of September 30, 2023, 118,565 shares of common stock remain eligible to be issued through equity-based instruments under the 2013 Equity Incentive Plan.

2014 Non-Employee Equity Compensation Plan

Effective on May 26, 2020, the Company’s stockholders approved the amendment and restatement of the 2014 Non-Employee Equity Compensation Plan to increase the number of shares reserved for issuance through equity-based instruments thereunder by 40,000 shares, bringing to 82,500 the total number of shares approved for issuance under that plan.

 

As of September 30, 2023, 29,137 shares of common stock remain eligible to be issued through equity-based instruments under the 2014 Non-Employee Equity Compensation Plan.

2015 Performance Share Unit Plan

Effective on June 16, 2021, the Company’s stockholders approved the amendment and restatement of the 2015 Performance Share Unit Plan to increase the number of shares reserved for issuance through equity-based instruments thereunder by 85,000 shares, bringing to 255,505 the total number of shares approved for issuance under that plan.

As of September 30, 2023, 106,272 shares of common stock remain eligible to be issued through equity-based instruments under the 2015 Performance Share Unit Plan.

 

2017 Equity Inducement Plan

On December 28, 2017, the Board approved the 2017 Equity Inducement Plan. Under the 2017 Equity Inducement Plan, the Board reserved 30,000 shares for the grant of RSUs. These grants will be administered by the Board or a committee of the Board. These awards will be granted to individuals who (a) are being hired as an employee by the Company or any subsidiary and such award is a material inducement to such person being hired; (b) are being rehired as an employee following a bona fide period of interruption of employment with the Company or any subsidiary; or (c) will become an employee of the Company or any subsidiary in connection with a merger or acquisition.

 

On July 20, 2022, the Board increased the number of shares of common stock reserved and available for issuance under the 2017 Equity Inducement Plan by 100,000 shares. As of September 30, 2023, 48,834 shares of common stock remain available to be issued through equity-based instruments under the 2017 Equity Inducement Plan.

Employee Stock Purchase Plan

In April 2015, the Company’s Board approved the ESPP, under which 30,000 shares of common stock have been reserved for purchase by the Company’s employees, subject to the approval by the Company’s stockholders. On May 21, 2015, the Company’s stockholders approved the ESPP. Effective on June 14, 2023, the Company’s stockholders approved the amendment and restatement of the ESPP to increase the number of shares reserved for issuance through equity-based instruments thereunder by 25,000 shares, bringing to 102,500 the total number of shares approved for issuance under that plan. Under the ESPP, employees may designate an amount not less than 1% but not more than 10% of their annual compensation for the purchase of Company shares. An offering period shall be six months in duration commencing on or about January 1 and July 1 of each year. The exercise price of the option will be the lesser of 85% of the fair market of the common stock on the first business day of the offering period and 85% of the fair market value of the common stock on the applicable exercise date.

Note 6 – Stock-Based Compensation, continued

As of September 30, 2023, 18,741 shares of common stock remain eligible to be issued under the ESPP. Employees contributed $3,493 through payroll withholdings to the ESPP as of September 30, 2023 for the current offering period which ends on December 31, 2023 with shares deemed delivered on that date.

 

Stock Option Activity

In February 2022, the Board granted our Chief Executive Officer 15,000 stock options under the 2013 Equity Incentive Plan at an exercise price of $25.40 per share with half of the options vesting on the second anniversary of the vesting start date and a quarter of the options vesting on each of the two following anniversaries.

The Company estimated the fair value of stock options granted during the second quarter of 2022 using the Black-Scholes option pricing model. No stock options were granted during the nine months ended September 30, 2023. The fair values of stock options granted during the second quarter of 2022 were estimated using the following assumptions:

 

 

 

Three Months Ended June 30,

 

 

 

2022

 

Stock price

 

$

25.40

 

Dividend yield

 

 

0

%

Expected volatility

 

 

108

%

Risk-free interest rate

 

 

1.92

%

Expected life

 

5.6 years

 

 

The following is a summary of the Company’s stock option activity during the nine months ended September 30, 2023:

 

 

 

Number of
Options

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Life In
Years

 

 

Intrinsic
Value

 

Outstanding at January 1, 2023

 

 

15,013

 

 

$

25.42

 

 

 

8.9

 

 

$

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(13

)

 

 

49.80

 

 

 

 

 

 

 

Outstanding at September 30, 2023

 

 

15,000

 

 

$

25.40

 

 

 

8.2

 

 

$

 

Exercisable at January 1, 2023

 

 

13

 

 

$

49.80

 

 

 

0.3

 

 

$

 

Vested

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(13

)

 

 

49.80

 

 

 

 

 

 

 

Exercisable at September 30, 2023

 

 

 

 

$

 

 

 

 

 

$

 

 

As of September 30, 2023, the unamortized fair value of options was $169,700. The unamortized amount will be expensed over a weighted average period of 2.1 years.

PSUs

 

PSUs are grants that vest upon the achievement of certain performance goals. The goals are commonly related to the Company’s revenue and achievement of sales and marketing goals.

Note 6 – Stock-Based Compensation, continued

On July 20, 2022, the Board granted the Company’s Chief Executive Officer, Cesar Johnston, up to 14,350 PSUs under the Company’s 2015 Performance Share Unit Plan pursuant to the terms of Mr. Johnston’s offer letter with the Company (See Note 4 – Commitments and Contingencies). The up to 14,350 PSUs that have been approved shall vest as follows: (a) up to 9,350 PSU shares shall vest on December 31, 2022, subject to Mr. Johnston’s continued service as Chief Executive Officer and the achievement, to be determined in the Compensation Committee’s sole discretion, by Mr. Johnston of certain performance metrics previously determined by the Compensation Committee and approved by the Board, (b) up to an additional 2,500 PSU shares shall vest on December 31, 2023, subject to Mr. Johnston’s continued service as Chief Executive Officer and the achievement, to be determined in the Compensation Committee’s sole discretion, by Mr. Johnston of certain performance metrics determined and granted by the Board on May 17, 2023, and (c) up to an additional 2,500 PSU shares shall vest on December 31, 2024, subject to Mr. Johnston’s continued service as Chief Executive Officer and the achievement, to be determined in the Compensation Committee’s sole discretion, by Mr. Johnston of certain performance metrics to be recommended by the Compensation Committee and approved by the Board at a subsequent date. On December 31, 2022, 6,779 PSUs were achieved, vested and deemed delivered on that date. As of September 30, 2023, the performance criteria for the additional up to 2,500 PSUs that shall vest on December 31, 2024 had not been approved by the Board.

 

As of September 30, 2023, the unamortized value of outstanding PSUs was $9,848. The unamortized amount will be expensed over a period of 0.3 years. A summary of the activity related to PSUs for the nine months ended September 30, 2023 is presented below:

 

 

 

Total

 

 

Weighted
Average Grant
Date Fair Value

 

Outstanding at January 1, 2023

 

 

 

 

$

 

PSUs granted

 

 

2,500

 

 

 

6.20

 

PSUs forfeited

 

 

 

 

 

 

PSUs vested

 

 

 

 

 

 

Outstanding at September 30, 2023

 

 

2,500

 

 

$

6.20

 

 

RSUs

During the nine months ended September 30, 2023, the Compensation Committee granted various employees RSUs covering 3,439 shares of common stock under the 2013 Equity Incentive Plan. The awards vest over five years.

During the nine months ended September 30, 2023, the Compensation Committee granted various non-employees RSUs covering 6,223 shares of common stock under the 2014 Non-Employee Equity Compensation Plan. The awards vest over terms ranging from one to four years.

During the nine months ended September 30, 2023, the Compensation Committee granted various employees RSUs covering 30,750 shares of common stock under the 2017 Equity Inducement Plan. The awards vest over four years.

 

As of September 30, 2023, the unamortized fair value of the outstanding RSUs was $1,428,206. The unamortized amount will be expensed over a weighted average period of 1.9 years. A summary of the activity related to RSUs for the nine months ended September 30, 2023 is presented below:

 

 

 

Total

 

 

Weighted
Average
Grant
Date Fair
Value

 

Outstanding at January 1, 2023

 

 

108,251

 

 

$

32.67

 

RSUs granted

 

 

40,412

 

 

 

12.81

 

RSUs forfeited

 

 

(10,340

)

 

 

28.02

 

RSUs vested

 

 

(54,636

)

 

 

32.26

 

Outstanding at September 30, 2023

 

 

83,687

 

 

$

23.92

 

 

 

Note 6 – Stock-Based Compensation, continued

Employee Stock Purchase Plan (“ESPP”)

The current offering period under the ESPP began on July 1, 2023 and will conclude on December 31, 2023. The recently completed offering period under the ESPP started on January 1, 2023 and concluded on June 30, 2023. During the year ended December 31, 2022, there were two offering periods. The first offering period began on January 1, 2022 and concluded on June 30, 2022. The second offering period began on July 1, 2022 and concluded on December 31, 2022.

The weighted-average grant-date fair value of the purchase option for each designated share purchased under the ESPP was approximately $4.05 and $7.29 for the nine months ended September 30, 2023 and 2022, respectively, which represents the fair value of the option, consisting of three main components: (i) the value of the discount on the enrollment date, (ii) the proportionate value of the call option for 85% of the stock and (iii) the proportionate value of the put option for 15% of the stock. The Company recognized compensation expense for the ESPP of $1,412 and $22,084 for the three months ended September 30, 2023 and 2022, respectively. The Company recognized compensation expense for the ESPP of $42,419 and $104,485 for the nine months ended September 30, 2023 and 2022, respectively.

The Company estimated the fair value of ESPP purchase options granted during the nine months ended September 30, 2023 and 2022 using the Black-Scholes option pricing model. The fair values of ESPP purchase options granted were estimated using the following assumptions:

 

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

2022

 

Stock price

 

$4.80-16.72

 

 

$19.20-$25.00

 

Dividend yield

 

 

0

%

 

 

0

%

Expected volatility

 

59% - 67%

 

 

61% - 68%

 

Risk-free interest rate

 

4.42% - 5.47%

 

 

0.19% - 2.52%

 

Expected life

 

6 months

 

 

6 months

 

 

 

Stock-Based Compensation Expense

The following tables summarize total stock-based compensation costs recognized for the three and nine months ended September 30, 2023 and 2022:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Stock options

 

$

21,564

 

 

$

21,564

 

 

$

63,989

 

 

$

53,207

 

RSUs

 

 

341,443

 

 

 

586,652

 

 

 

1,273,380

 

 

 

1,933,301

 

PSUs

 

 

4,488

 

 

 

67,922

 

 

 

15,089

 

 

 

67,922

 

ESPP

 

 

1,412

 

 

 

22,084

 

 

 

42,419

 

 

 

104,485

 

Total

 

$

368,907

 

 

$

698,222

 

 

$

1,394,877

 

 

$

2,158,915

 

 

The total amount of stock-based compensation was reflected within the statements of operations as:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Research and development

 

$

138,976

 

 

$

273,923

 

 

$

557,767

 

 

$

922,447

 

Sales and marketing

 

 

84,491

 

 

 

109,702

 

 

 

292,850

 

 

 

344,478

 

General and administrative

 

 

145,440

 

 

 

314,597

 

 

 

544,260

 

 

 

804,328

 

Severance expense

 

 

 

 

 

 

 

 

 

 

 

87,662

 

Total

 

$

368,907

 

 

$

698,222

 

 

$

1,394,877

 

 

$

2,158,915